PRCT

In the past six months, PROCEPT BioRobotics Corp. experienced several stock-impacting events including its Q1 2026 earnings call and participation in multiple healthcare conferences. Positive clinical updates included the completion of enrollment in the WATER IV prostate cancer study and strengthened AUA guideline recommendations for Aquablation therapy. However, Q2 2026 financial results revealed a wider-than-expected net loss and an EPS miss, along with softer procedure volume growth, leading to analyst downgrades. A securities class action lawsuit was filed alleging misrepresentation of sales practices. Amidst these events, CEO Larry Wood purchased shares, but the company's stock price saw significant declines, falling 49.82% between September 2025 and September 2026, 46.99% over the last year, and 13.29% in the last month as of October 2026.